Juno Therapeutics Inc (JUNO)

29.00
NASDAQ : Health Care
Prev Close 26.98
Day Low/High 26.62 / 29.25
52 Wk Low/High 17.52 / 42.98
Avg Volume 1.72M
Exchange NASDAQ
Shares Outstanding 106.10M
Market Cap 2.86B
EPS -2.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Biotech Movers: NewLink, Inovio, Juno

Biotech Movers: NewLink, Inovio, Juno

NewLink Genetics, Inovio Pharmaceuticals and Juno Therapeutics were among the biotech stock movers in premarket trading on Thursday.

Thursday's 'Triathlon of Terror' Is Overblown: Cramer's 'Mad Money' Recap (Wednesday 6/7/17)

Thursday's 'Triathlon of Terror' Is Overblown: Cramer's 'Mad Money' Recap (Wednesday 6/7/17)

Comey's testimony? U.K. elections? Eurozone news? These can be new buying opportunities, says Jim Cramer.

Juno Therapeutics To Present At The Goldman Sachs 38th Annual Global Healthcare Conference

Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentation at the Goldman Sachs 38 th Annual Global Healthcare Conference at 10:00 a.

Juno Therapeutics Presents Updated TRANSCEND NHL 001 Trial Data Demonstrating High Durable Response Rates In Patients With Relapsed Or Refractory CD19+ Aggressive Non-Hodgkin Lymphoma

Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced updated data from the TRANSCEND trial of JCAR017 in relapsed...

Juno Therapeutics Mounts CAR-T Comeback With Strong Lymphoma Study Results

Juno Therapeutics Mounts CAR-T Comeback With Strong Lymphoma Study Results

Rivals Kite Pharma and Novartis are still out in front, but updated efficacy and safety data from Juno's JCAR017 program in patients with aggressive non-Hodgkin's lymphoma are very competitive.

Insiders Love Bioverativ, Juno Therapeutics and More

Insiders Love Bioverativ, Juno Therapeutics and More

Insiders at Bioverativ, Juno Therapeutics and three other companies have been buying up shares of their own stock recently.

JUNO: Insiders vs. Shorts

The most recent short interest data was recently released for the 05/15/2017 settlement date, and Juno Therapeutics Inc is one of the most shorted stocks of the Russell 3000, based on 10.78 "days to cover" versus the median component at 4.71. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Juno Therapeutics Appoints Jay Flatley To Board Of Directors

Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced it has appointed Jay Flatley to its Board of Directors.

Bluebird, Kite and Juno Delivering CAR-T Cancer Study Updates to ASCO '17 Meeting

Bluebird, Kite and Juno Delivering CAR-T Cancer Study Updates to ASCO '17 Meeting

The drug companies engineering T-cells to recognize and kill cancer, otherwise known as chimeric antigen receptor T-cells, or CAR-Ts, will be busy at the ASCO annual meeting in June.

Juno Therapeutics To Present Key Clinical Data Updates On JCAR017 And JCAR014 At The 2017 American Society Of Clinical Oncology Annual Meeting

Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced that it will present key clinical updates in partnership with...

Here Are Some of Congress' Favorite Stocks

Here Are Some of Congress' Favorite Stocks

While hard at work in Washington, a handful of members of Congress have also been busy trading stocks.

Juno Therapeutics To Present At The Bank Of America Merrill Lynch 2017 Health Care Conference

Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentation at the Bank of America Merrill Lynch 2017 Health Care Conference at 3:40 p.

Kite Pharma Discloses CAR-T Patient Death, Rattling Investors

Kite Pharma Discloses CAR-T Patient Death, Rattling Investors

The death rattled Kite investors because death from brain swelling, or cerebral edema, is the same severe toxic event that scuttled a competing CAR-T therapy from Juno Therapeutics.

Juno Therapeutics Reports First Quarter 2017 Financial Results

Juno Therapeutics, Inc. (NASDAQ:JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today reported financial results and business highlights for the first quarter...

Nasdaq Nearing Overbought Status

Optical equipment maker Acacia isn't making higher highs; Juno Therapeutics is facing resistance.

Juno Therapeutics To Report First Quarter 2017 Financial Results On Thursday, May 4

Juno Therapeutics, Inc. (NASDAQ: JUNO) will announce financial results for the first quarter 2017 on Thursday, May 4, 2017, after the close of U.

Juno Therapeutics Appoints Rupert Vessey To Board Of Directors

Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced it has appointed to its Board of Directors Dr.

Juno Therapeutics Appoints Sunil Agarwal As President Of Research And Development

Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced it has appointed Sunil Agarwal, M.

Biotech Premarket Movers: Aurinia, Puma, PTC, Juno

Biotech Premarket Movers: Aurinia, Puma, PTC, Juno

Aurinia Pharmaceuticals, Puma Biotechnology, PTC Therapeutics and Juno Therapeutics were among the biotech stock movers in premarket trading on Thursday.

Juno Therapeutics Reports Fourth Quarter And 2016 Financial Results

Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today reported financial results and business highlights for the fourth quarter...

Juno Therapeutics To Present At March 2017 Investor Conferences

Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentations at two investor conferences in March.

5 Earnings Short-Squeeze Trade Ideas

5 Earnings Short-Squeeze Trade Ideas

These heavily shorted stocks could get squeezed higher, if they report positive earnings this week.

Kite Pharma CAR-T Cancer Therapy Shows Strong, Durable Effect in Lymphoma Patients

Kite Pharma CAR-T Cancer Therapy Shows Strong, Durable Effect in Lymphoma Patients

Kite intends to submit a marketing application for KTE-C19 to the U.S. Food and Drug Administration by the end of March.

Juno Therapeutics To Report Full Year And Fourth Quarter 2016 Financial Results On Wednesday, March 1

Juno Therapeutics, Inc. (NASDAQ:JUNO) will announce financial results for the fourth quarter and year ended December 31, 2016, on Wednesday, March 1, 2017, after the close of U.

Juno Therapeutics To Present At The Leerink Partners 6th Annual Global Healthcare Conference

Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentation at the Leerink Partners 6 th Annual Global Healthcare Conference at 10:00 a.

Side Effect Kills Cancer Patient in Stemline Therapeutics Drug Trial; Company Raises Money

Side Effect Kills Cancer Patient in Stemline Therapeutics Drug Trial; Company Raises Money

Stemline's SL-401 has demonstrated robust overall tumor response rates in its clinical trial, but the drug is also now tied to three patient deaths from capillary leak syndrome.

Corsee D. Sanders, Ph.D., Executive Vice President And Head Of Development Operations, Juno Therapeutics (Photo: Business Wire)

Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced the appointment of Corsee D.

Noteworthy Friday Option Activity: JUNO, SHLD, LJPC

Noteworthy Friday Option Activity: JUNO, SHLD, LJPC

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Juno Therapeutics Inc , where a total of 13,632 contracts have traded so far, representing approximately 1.4 million underlying shares. That amounts to about 77.9% of JUNO's average daily trading volume over the past month of 1.7 million shares.